Growth characteristics in individuals with osteogenesis imperfecta in North America: results from a multicenter study.
Growth
Height
Natural history study
Osteogenesis imperfecta
Weight
Journal
Genetics in medicine : official journal of the American College of Medical Genetics
ISSN: 1530-0366
Titre abrégé: Genet Med
Pays: United States
ID NLM: 9815831
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
received:
18
10
2017
accepted:
09
04
2018
pubmed:
5
7
2018
medline:
19
4
2019
entrez:
5
7
2018
Statut:
ppublish
Résumé
Osteogenesis imperfecta (OI) predisposes people to recurrent fractures, bone deformities, and short stature. There is a lack of large-scale systematic studies that have investigated growth parameters in OI. Using data from the Linked Clinical Research Centers, we compared height, growth velocity, weight, and body mass index (BMI) in 552 individuals with OI. Height, weight, and BMI were plotted on Centers for Disease Control and Prevention normative curves. In children, the median z-scores for height in OI types I, III, and IV were -0.66, -6.91, and -2.79, respectively. Growth velocity was diminished in OI types III and IV. The median z-score for weight in children with OI type III was -4.55. The median z-scores for BMI in children with OI types I, III, and IV were 0.10, 0.91, and 0.67, respectively. Generalized linear model analyses demonstrated that the height z-score was positively correlated with the severity of the OI subtype (P < 0.001), age, bisphosphonate use, and rodding (P < 0.05). From the largest cohort of individuals with OI, we provide median values for height, weight, and BMI z-scores that can aid the evaluation of overall growth in the clinic setting. This study is an important first step in the generation of OI-specific growth curves.
Identifiants
pubmed: 29970925
doi: 10.1038/s41436-018-0045-1
pii: S1098-3600(21)04612-8
pmc: PMC6320321
mid: NIHMS961139
doi:
Substances chimiques
Diphosphonates
0
Pamidronate
OYY3447OMC
Types de publication
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
275-283Subventions
Organisme : NIGMS NIH HHS
ID : T32 GM007526
Pays : United States
Organisme : NIAMS NIH HHS
ID : U54 AR068069
Pays : United States
Organisme : NICHD NIH HHS
ID : U54 HD083092
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002369
Pays : United States
Investigateurs
David R Eyre
(DR)
Deborah Krakow
(D)
Laura Tosi
(L)
Cathleen L Raggio
(CL)
Eric S Orwoll
(ES)
Eric T Rush
(ET)
Références
Rauch F, Glorieux FH. Osteogenesis imperfecta. Lancet. 2004;363:1377–85.
doi: 10.1016/S0140-6736(04)16051-0
Sykes B, Wordsworth P, Ogilvie D, et al. Osteogenesis imperfecta is linked to both type I collagen structural genes. Lancet. 1986;328:69–72.
doi: 10.1016/S0140-6736(86)91609-0
Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet. 1979;16:101–16.
doi: 10.1136/jmg.16.2.101
Bellur S, Jain M, Cuthbertson D, et al. Cesarean delivery is not associated with decreased at-birth fracture rates in osteogenesis imperfecta. Genet Med. 2016;18:570–6.
doi: 10.1038/gim.2015.131
Vetter U, Pontz B, Zauner E, et al. Osteogenesis imperfecta: a clinical study of the first ten years of life. Calcif Tissue Int. 1992;50:36–41.
doi: 10.1007/BF00297295
Aglan MS, Zaki ME, Hosny L, et al. Anthropometric measurements in Egyptian patients with osteogenesis imperfecta. Am J Med Genet A. 2012;158 A:2714–8.
doi: 10.1002/ajmg.a.35529
Germain-Lee EL, Brennen FS, Stern D, et al. Cross-sectional and longitudinal growth patterns in osteogenesis imperfecta: implications for clinical care. Pediatr Res. 2015;79:489–95.
doi: 10.1038/pr.2015.230
Lund A, Müller J, Skovby F. Anthropometry of patients with osteogenesis imperfecta. Arch Dis Child. 1999;80:524–8.
doi: 10.1136/adc.80.6.524
Engelbert RH, Gerver WJ, Breslau-Siderius LJ, et al. Spinal complications in osteogenesis imperfecta: 47 patients 1–16 years of age. Acta Orthop Scand. 1998;69:283–6.
doi: 10.3109/17453679809000931
Engelbert RH, Uiterwaal CS, Gerver WJ, et al. Osteogenesis imperfecta in childhood: impairment and disability. A prospective study with 4-year follow-up. Arch Phys Med Rehabil. 2004;85:772–8.
doi: 10.1016/j.apmr.2003.08.085
Zeitlin L, Rauch F, Plotkin H, et al. Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV. Pediatrics. 2003;111:1030–6.
doi: 10.1542/peds.111.5.1030
Hamza RT, Abdelaziz TH, Elakkad M. Anthropometric and nutritional parameters in Egyptian children and adolescents with osteogenesis imperfecta. Horm Res Paediatr. 2015;83:311–20.
doi: 10.1159/000374111
Graff K, Syczewska M. Developmental charts for children with osteogenesis imperfecta, type I (body height, body weight and BMI). Eur J Pediatr. 2017;176:311–6.
doi: 10.1007/s00431-016-2839-y
Patel RM, Nagamani SCS, Cuthbertson D, et al. A cross-sectional multicenter study of osteogenesis imperfecta in North America—results from the Linked Clinical Research Centers. Clin Genet. 2015;87:133–40.
doi: 10.1111/cge.12409
Kuczmarski RJ, Ogden CL, Guo SS, et al. 2000 CDC growth charts for the United States: methods and development. Vital Health Stat. 2002;11:1–190.
Nwosu BU, Lee MM. Evaluation of short and tall stature in children. Am Fam Physician. 2008;78:597–604.
pubmed: 18788236
Tanner JM, Davies PS. Clinical longitudinal standards for height and height velocity for North American children. J Pediatr. 1985;107:317–29.
doi: 10.1016/S0022-3476(85)80501-1
Belt-Niedbala BJ, Ekvall S, Cook CM, et al. Linear growth measurement: a comparison of single arm-lengths and arm-span. Dev Med Child Neurol. 1986;28:319–24.
doi: 10.1111/j.1469-8749.1986.tb03880.x
Bishop N, Adami S, Ahmed SF, et al. Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial. Lancet. 2013;382:1424–32.
doi: 10.1016/S0140-6736(13)61091-0
Rauch F, Munns CF, Land C, et al. Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study. J Bone Miner Res. 2009;24:1282–9.
doi: 10.1359/jbmr.090213
Sakkers R, Kok D, Engelbert R, et al. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study. Lancet. 2004;363:1427–31.
doi: 10.1016/S0140-6736(04)16101-1
Seikaly MG, Kopanati S, Salhab N, et al. Impact of alendronate on quality of life in children with osteogenesis imperfecta. J Pediatr Orthop. 2005;25:786–91.
doi: 10.1097/01.bpo.0000176162.78980.ed
Letocha AD, Cintas HL, Troendle JF, et al. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement. J Bone Miner Res. 2005;20:977–86.
doi: 10.1359/JBMR.050109
Anissipour AK, Hammerberg KW, Caudill A, et al. Behavior of scoliosis during growth in children with osteogenesis imperfecta. J Bone Joint Surg Am. 2014;96:237–43.
doi: 10.2106/JBJS.L.01596
Marini JC, Bordenick S, Heavner G, et al. Evaluation of growth hormone axis and responsiveness to growth stimulation of short children with osteogenesis imperfecta. Am J Med Genet. 1993;45:261–4.
doi: 10.1002/ajmg.1320450223
Marini JC, Bordenick S, Heavner G, et al. The growth hormone and somatomedin axis in short children with osteogenesis imperfecta. J Clin Endocrinol Metab. 1993;76:251–6.
pubmed: 8421094
Grafe I, Yang T, Alexander S, et al. Excessive transforming growth factor-β signaling is a common mechanism in osteogenesis imperfecta. Nat Med. 2014;20:670–5.
doi: 10.1038/nm.3544
Keene DR, San Antonio JD, Mayne R, et al. Decorin binds near the C terminus of type I collagen. J Biol Chem. 2000;275:21801–4.
doi: 10.1074/jbc.C000278200
Takeuchi Y, Kodama Y, Matsumoto T. Bone matrix decorin binds transforming growth factor-beta and enhances its bioactivity. J Biol Chem. 1994;269:32634–8.
pubmed: 7798269
Markmann A, Hausser H, Schönherr E, et al. Influence of decorin expression on transforming growth factor-beta-mediated collagen gel retraction and biglycan induction. Matrix Biol. 2000;19:631–6.
doi: 10.1016/S0945-053X(00)00097-4
Yang T, Grafe I, Bae Y, et al. E-selectin ligand 1 regulates bone remodeling by limiting bioactive TGF-β in the bone microenvironment. Proc Natl Acad Sci. 2013;110:7336–41.
doi: 10.1073/pnas.1219748110
Land C, Rauch F, Munns CF, et al. Vertebral morphometry in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate treatment. Bone. 2006;39:901–6.
doi: 10.1016/j.bone.2006.04.004
Glorieux FH, Bishop NJ, Plotkin H, et al. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med. 1998;339:947–52.
doi: 10.1056/NEJM199810013391402
Dimeglio LA, Ford L, McClintock C, et al. A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta. J Pediatr Endocrinol Metab. 2005;18:43–53.
doi: 10.1515/JPEM.2005.18.1.43
Gatti D, Antoniazzi F, Prizzi R, et al. Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study. J Bone Miner Res. 2004;20:758–63.
doi: 10.1359/JBMR.041232
Barros ER, Saraiva GL, de Oliveira TP, et al. Safety and efficacy of a 1-year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta. J Pediatr Endocrinol Metab. 2012;25:485–91.
doi: 10.1515/jpem-2012-0016
Bishop N, Harrison R, Ahmed F, et al. A randomized, controlled dose-ranging study of risedronate in children with moderate and severe osteogenesis imperfecta. J Bone Miner Res. 2010;25:32–40.
doi: 10.1359/jbmr.090712
Hald JD, Evangelou E, Langdahl BL, et al. Bisphosphonates for the prevention of fractures in osteogenesis imperfecta: meta-analysis of placebo-controlled trials. J Bone Miner Res. 2015;30:929–33.
doi: 10.1002/jbmr.2410
Dwan K, Phillipi CA, Steiner RD, et al. Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev. 2014;23:CD005088.
Palomo T, Glorieux FH, Schoenau E, et al. Body composition in children and adolescents with osteogenesis imperfecta. J Pediatr. 2016;169:232–7.
doi: 10.1016/j.jpeds.2015.10.058